Accelerated Disease Progression after Discontinuation of Sorafenib in a Patient with Metastatic Papillary Thyroid Cancer

Distant metastases from papillary thyroid carcinoma (PTC) are rare and are associated with a poor prognosis. Here, we describe a patient with metastatic PTC who was treated with a tyrosine kinase inhibitor (TKI, sorafenib) for several months that was acutely exacerbated by discontinuation. A 43-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Kyung-Jin, Kim, Woohyeon, Kim, Eun Hee, Kim, Min-Hee, Lim, Dong-Jun, Kang, Moo-Il, Cha, Bong-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192805/
https://www.ncbi.nlm.nih.gov/pubmed/25309799
http://dx.doi.org/10.3803/EnM.2014.29.3.388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192805/
https://www.ncbi.nlm.nih.gov/pubmed/25309799
http://dx.doi.org/10.3803/EnM.2014.29.3.388

Ejemplares similares